Embibatinib clinical trials
Also written HS-10382 and MK-4208.
How each study uses Embibatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Embibatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Jiangsu Hansoh Pharmaceutical Co., Ltd. (4) · Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Embibatinib.
- Feb 2027A Phase I Study to Evaluate the Effect of Food on the Pharmacokinetics of HS-10382 Tablets in Healthy ParticipantsPhase 1 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses Embibatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Phase I Study to Evaluate the Effect of Food on the Pharmacokinetics of HS-10382 Tablets in Healthy ParticipantsNot yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07933224Written as HS-10382
- A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07885293Written as HS-10382
- A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)RecruitingPhase 1/2Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT06163430Written as MK-4208
- Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)Not yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06530810Written as HS-10382+Flumatinib
- A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.RecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05367700Written as HS-10382(Part 1: Dose escalation)
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)CompletedPhase 1Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT07838987Written as Embibatinib
- A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)CompletedPhase 1Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT07839000Written as TERN-701
What changed recently
From the registry's own updates since Oct 18, 2026.